• 1
    El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer EW, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 81725.
  • 2
    Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 311.
  • 3
    Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJJr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telengiectasia. Cell 1992; 71: 58797.
  • 4
    Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799805.
  • 5
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 32331.
  • 6
    Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with Adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 2658.
  • 7
    Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 8524.
  • 8
    Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lellas JM, Dumont X, Ferrara P, McKeon F, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 80919.
  • 9
    Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4: 83943.
  • 10
    Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998; 4: 7478.
  • 11
    Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiples products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 30516.
  • 12
    Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99103.
  • 13
    Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 63641.
  • 14
    Zaika AI, Slade N, Erster SH, Sansone C, Joseph TW, Pearl M, Chalas E, Moll U. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73 is up-regulated in human tumors. J Exp Med 2002; 196: 76580.
  • 15
    Bénard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Human Mutat 2003; 21: 18291.
  • 16
    Jost CA, Marin MC, Kaelin WGJr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 1914.
  • 17
    Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998; 58: 50615.
  • 18
    Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S, Ishioka C. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 1999; 59: 27816.
  • 19
    Miro-Mur F, Meiller A, Haddada H, May E. p73α expression induces both accumulation and activation of wt-p53 independent of the p73α transcriptional activity. Oncogene 2003; 22: 54516.
  • 20
    Fang L, Lee SW, Aaronson SA. Comparative analysis of p73 and p53 regulation and effector functions. J Cell Biol 1999; 147: 82330.
  • 21
    Vikhanskaya F, D'Incalci M, Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res 2000; 28: 5139.
  • 22
    Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 1999; 399: 80913.
  • 23
    Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WGJr, Levrero M, Wang JYG. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 8069.
  • 24
    Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 8147.
  • 25
    Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 5604.
  • 26
    Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387402.
  • 27
    Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WGJr. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 40310.
  • 28
    Vayssade M, Faridoni-Laurens L, Bénard J, Ahomadegbe JC. Expression of p53-family members and associated target molecules in breast cancer cell lines in response to vincristine treatment. Biochem Pharmacol 2002; 63: 16119.
  • 29
    Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 121727.
  • 30
    Guillot C, Falette N, Paperin MP, Courtois S, Gentil-Perret A, Treilleux I, Ozturk M, Puisieux A. p21WAF1/CIP1 response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene 1997; 14: 4552.
  • 31
    Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res 1987; 47: 51418.
  • 32
    Nakano K, Balint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000; 19: 42839.
  • 33
    Elbashir SM, Harboth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 4948.
  • 34
    Yuan R, Meng Q, Hu H, Goldberd ID, Rosen EM, Fan S. p53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemother Pharmacol 2001; 47: 1619.
  • 35
    Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A. Autoinhibitory regulation of p73 by delta Np73 to modulate cell survival and death through a p73-specific target element within the delta Np73 promoter. Mol Cell Biol 2002; 22: 257585.
  • 36
    Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo A. ΔNp73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 23: 3796803.